Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has mat...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroh, M, Carlile, DJ, Li, C-C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J-E, Xhu, Z-X, Morcos, PN, Davis, JD, Phipps, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592528/
https://www.ncbi.nlm.nih.gov/pubmed/26451328
http://dx.doi.org/10.1002/psp4.12014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592528/
https://www.ncbi.nlm.nih.gov/pubmed/26451328
http://dx.doi.org/10.1002/psp4.12014

Ejemplares similares